CANbridge Pharmaceuticals Inc. (1228.HK)

HKD 0.14

(-8.05%)

Total Liabilities Summary of CANbridge Pharmaceuticals Inc.

  • CANbridge Pharmaceuticals Inc.'s latest annual total liabilities in 2023 was 435.15 Million CNY , up 10.59% from previous year.
  • CANbridge Pharmaceuticals Inc.'s latest quarterly total liabilities in 2024 Q1 was 529.18 Million CNY , up 21.61% from previous quarter.
  • CANbridge Pharmaceuticals Inc. reported annual total liabilities of 393.49 Million CNY in 2022, up 97.6% from previous year.
  • CANbridge Pharmaceuticals Inc. reported annual total liabilities of 199.13 Million CNY in 2021, down -91.46% from previous year.
  • CANbridge Pharmaceuticals Inc. reported quarterly total liabilities of 529.18 Million CNY for 2024 Q2, down 0.0% from previous quarter.
  • CANbridge Pharmaceuticals Inc. reported quarterly total liabilities of 445.6 Million CNY for 2023 Q2, down 0.0% from previous quarter.

Annual Total Liabilities Chart of CANbridge Pharmaceuticals Inc. (2023 - 2019)

Historical Annual Total Liabilities of CANbridge Pharmaceuticals Inc. (2023 - 2019)

Year Total Liabilities Total Liabilities Growth
2023 435.15 Million CNY 10.59%
2022 393.49 Million CNY 97.6%
2021 199.13 Million CNY -91.46%
2020 2.33 Billion CNY 116.11%
2019 1.07 Billion CNY 0.0%

Peer Total Liabilities Comparison of CANbridge Pharmaceuticals Inc.

Name Total Liabilities Total Liabilities Difference
Uni-Bio Science Group Limited 152.81 Million HKD -184.75%
CK Life Sciences Int'l., (Holdings) Inc. 7.05 Billion HKD 93.835%